ASCO '13: Amgen's Cancer-Killing Virus Shows Skin-Cancer Survival Trend (Update)

ASCO '13: Amgen's Cancer-Killing Virus Shows Skin-Cancer Survival Trend 

TheStreet.com 
PD-1 refers to the drugs being developed by Bristol-Myers, Merck and Roche. "We're doing early safety studies, it's too early to comment but the interest in pursuing this approach is much higher today." In the Amgen phase III trial, more than 400 ... 

http://www.thestreet.com/story/11938587/1/asco-13-amgens-cancer-killing-virus-shows-skin-cancer-survival-trend.html?cm_ven=GOOGLEN


by world drug tracker
DR ANTHONY MELVIN CRASTO

A novel therapy for the most common form of lung cancer shows promise and seems to yield largely manageable side effects, according to new research that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology.

Promising New Therapy For Lung Cancer

Medical News Today 
I think if we learn how to use it appropriately, and manage the side effects effectively, it will be a good drug to have in our armamentarium." ... A phase 1 trial that was previously published showed that 33% of the patients with NSCLC responded to ...

http://www.medicalnewstoday.com/articles/261312.php


BY 
WORLD DRUG TRACKER
DR ANTHONY MELVIN CRASTO

Analysis Revealed that Glaxo Drugs Can Prolong Lives of Ovarian Cancer Patients up to 17 Months

Analysis Revealed that Glaxo Drugs Can Prolong Lives of Ovarian Cancer Patients up to 17 Months

Analysis Revealed that Glaxo Drugs Can Prolong Lives of Ovarian Cancer ... 
Headlines & Global NewsThe researchers conducted a large-scale Phase 3 trial on women with advanced ovarian cancer. The test was successful as it prolonged the lives of the patients without getting their disease worse for an average of 5.6 months. The American Society ... 

http://www.hngn.com/articles/4251/20130601/analysis-revealed-glaxo-drugs-prolong-lives-ovarian-cancer-patients-up.htm

According to the study presented last Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago, the oral drug Votrient- with generic name pazopanib formulated to block tumor growth- may be used as a maintenance drug by ovarian cancer patients after the surgery and chemotherapy

Phase 3 DECISION Trial Investigating the Use of Nexavar® (sorafenib)

Phase 3 DECISION Trial Investigating the Use of Nexavar® (sorafenib ...Sacramento BeeThe Phase 3 DECISION data will form the basis for regulatory submissions of sorafenib for the treatment of RAI-refractory differentiated thyroid cancer. Submission of a supplemental New Drug Application (sNDA) in the United States is planned for mid ...

http://www.sacbee.com/2013/06/02/5464658/phase-3-decision-trial-investigating.html

http://newdrugapprovals.wordpress.com/2013/06/02/incivo-telaprevir-receives-european-commission-approval-for-twice-daily-dosing-for-treatment-of-genotype-1-chronic-hepatitis-c-virus-hcv/

http://newdrugapprovals.wordpress.com/2013/06/02/incivo-telaprevir-receives-european-commission-approval-for-twice-daily-dosing-for-treatment-of-genotype-1-chronic-hepatitis-c-virus-hcv/

PROCESS FOR MANUFACTURE OF TELMISARTAN PATENT US2013137878 (A1)30 MAY 2013

http://newdrugapprovals.wordpress.com/2013/06/01/process-for-manufacture-of-telmisartan-patent-us2013137878-a130-may-2013/

Japan launches $100m initiative to develop drugs for poorest nations

 http://www.pharmatimes.com/Article/13-05-31/Japan_launches_100m_initiative_to_develop_drugs_for_poorest_nations.aspx